Clinical trial
24-hour IOP-lowering Effect of Brimonidine 0.1%
NCT00457795 · Allergan, Industry · Completed
Key facts
| NCT number | NCT00457795 |
|---|---|
| Title | 24-hour IOP-lowering Effect of Brimonidine 0.1% |
| Lead sponsor | Allergan, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Open-angle Glaucoma, Ocular Hypertension |
| Intervention type | Drug |
| Interventions | brimonidine 0.1% (Alphagan® P) |
| Enrollment | 15 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Apr 9, 2007 |
| Last update posted | Nov 24, 2011 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: